MSCs can exert their anti-tumor effects by interacting with macrophages in the TME (39, 41), and they have been reported to bias macrophages toward the “anti-inflammatory” M2 subtype, which is characterized by elevated IL-10 levels and reduced expression of iNOS and IL-12 (39, 41–43). The gene discussed is IL10; the disease is neoplasm.